Safety of once-or twice-daily dosing of non-vitamin K antagonist oral anticoagulants (NOACs) in patients with nonvalvular atrial fibrillation: A NOAC-TR study

Basit Öğe Kaydı
dc.contributor.authorEmren, Sadik Volkan
dc.contributor.authorZoghi, Mehdi
dc.contributor.authorBerilgen, Rida
dc.contributor.authorOzdemir, Ibrahim Halil
dc.contributor.authorCelik, Oguzhan
dc.contributor.authorCetin, Nurullah
dc.contributor.authorEnhos, Asim
dc.contributor.authorKoseoglu, Cemal
dc.contributor.authorAkyuz, Abdurrahman
dc.contributor.authorDogan, Volkan
dc.contributor.authorLevent, Fatih
dc.contributor.authorDereli, Yuksel
dc.contributor.authorDogan, Tolga
dc.contributor.authorBasaran, Ozcan
dc.contributor.authorKaraca, Ilgin
dc.contributor.authorKaraca, Ozkan
dc.contributor.authorOtlu, Yilmaz Omur
dc.contributor.authorOzmen, Caglar
dc.contributor.authorCosar, Selvi
dc.contributor.authorSumerkan, Mutlu
dc.contributor.authorGursul, Erdal
dc.contributor.authorInci, Sinan
dc.contributor.authorOnrat, Ersel
dc.contributor.authorErgene, Oktay
dc.date.accessioned2019-10-27T10:45:55Z
dc.date.available2019-10-27T10:45:55Z
dc.date.issued2018
dc.departmentEge Üniversitesien_US
dc.description.abstractOnce-daily dosing of non-vitamin K antagonist oral anticoagulants (NOACs) may increase patient adherence to treatment but may also be associated with a higher risk of bleeding. In this study, we investigated the adherence to once-or twice-daily dosing of NOACs and the risk of bleeding in nonvalvular atrial fibrillation (NVAF) patients. This multicenter cross-sectional study, conducted between 1 September 2015 and 28 February 2016, included 2214 patients receiving NOACs for at least 3 months, due to NVAF. Patients receiving once-daily or twice-daily NOAC doses were 1: 1 propensity score matched for baseline demographic characteristics and the presence of other diseases. The medication adherence was assessed by the 8-item Morisky Medication Adherence Scale. Risk factors were investigated in relation to minor and major bleeding. The mean age of patients was 71 +/- 10 years, and 53% of the patients were women. The medication adherence was lower in patients receiving twice-daily NOAC doses compared to once-daily-dose group (47% versus 53%, p = 0.001), and there was no difference between the groups in terms of minor (15% versus 16%, p = 0.292) and major bleeding (3% versus 3%, p = 0.796). Independent risk factors for bleeding were non-adherence to medication (OR: 1.62, 95% CI: 1.23-2.14, p = 0.001), presence of 3 or more other diseases (OR: 10.3, 95% CI: 5.3-20.3, p < 0.001), and HAS-BLED (Hypertension, Abnormal renal and liver function, Stroke, Bleeding, Labile INR, Elderly, Drugs or alcohol) score (OR: 4.84, 95% CI: 4.04-5.8, p < 0.001). In summary, the once-daily dose of NOACs was associated with increased patient adherence to medication, while it was not associated with bleeding complications.en_US
dc.identifier.doi10.17305/bjbms.2017.2279en_US
dc.identifier.endpage190en_US
dc.identifier.issn1512-8601
dc.identifier.issn1840-4812
dc.identifier.issue2en_US
dc.identifier.pmid28968197en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage185en_US
dc.identifier.urihttps://doi.org/10.17305/bjbms.2017.2279
dc.identifier.urihttps://hdl.handle.net/11454/31224
dc.identifier.volume18en_US
dc.identifier.wosWOS:000433285000010en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherAssoc Basic Medical Sci Federation Bosnia & Herzegovina Sarajevoen_US
dc.relation.ispartofBosnian Journal of Basic Medical Sciencesen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectDaily dosingen_US
dc.subjectbleedingen_US
dc.subjectmedication adherenceen_US
dc.subjectnon-vitamin K antagonist oral anticoagulantsen_US
dc.subjectself-reporten_US
dc.subjectNOACsen_US
dc.subjectnonvalvular atrial fibrillationen_US
dc.subjectNVAFen_US
dc.titleSafety of once-or twice-daily dosing of non-vitamin K antagonist oral anticoagulants (NOACs) in patients with nonvalvular atrial fibrillation: A NOAC-TR studyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu